A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer

Jin‐Ji Yang, Jian Fang, Yongqian Shu, Jianhua Chang, Gongyan Chen, Jian He, Wěi Li, Xiaoqing Liu, Nong Yang, Caicun Zhou, Jian Huang, Melanie M. Frigault, Ryan J. Hartmaier, Ghada F. Ahmed, Coumaran Égile, Shethah Morgan, Remy B. Verheijen, Anders Mellemgaard, Liu Yang, Yi‐Long Wu